Psilocybin for the Treatment of Migraine Headache

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate the effects of oral psilocybin in migraine headache. Subjects will each receive a dose of placebo and a dose of psilocybin approximately 14 days apart. Subjects will be randomized to the order of treatment and they will be randomized to receive either low or high dose psilocybin. Subjects will maintain a headache diary prior to, during, and after the treatments in order to document headache frequency and intensity, as well as associated symptoms. This preliminary study will inform on the basic effects of psilocybin in migraine headache and inform on the design of larger, more definitive studies.

Clinical Trial Description

The number of arms reflects the design of the enhanced blinding method. The final enrollment number reflects the number of subjects participating in study procedures. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03341689
Study type	Interventional
Source	Yale University
Contact
Status	Completed
Phase	Phase 1
Start date	November 1, 2017
Completion date	October 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04084314` - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study	Phase 4
Not yet recruiting	`NCT05943457` - Vitamin K2 Supplementation in Adult Episodic Migraine	N/A
Completed	`NCT01211145` - Zomig - Treatment of Acute Migraine Headache in Adolescents	Phase 4
Completed	`NCT00530517` - A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack	Phase 2
Completed	`NCT00898677` - Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)	Phase 3
Completed	`NCT03971071` - A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache	Phase 4
Withdrawn	`NCT02706015` - Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks	Phase 3
Completed	`NCT02518464` - Ticagrelor Therapy for RefrACTORy Migraine Study	Phase 4
Terminated	`NCT02375789` - Intranasal Cooling for Symptomatic Relief of Migraine	N/A
Terminated	`NCT00391755` - A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches	Phase 4
Completed	`NCT03401346` - Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults	Phase 1
Completed	`NCT05085483` - Ketone for Migraine Prevention	N/A
Completed	`NCT01604785` - Low-dose Propofol for Pediatric Migraine	Phase 2/Phase 3
Terminated	`NCT00804973` - Study in Participants With Acute Migraines Headaches	Phase 2
Completed	`NCT01630044` - Neurostimulation Device for Treatment of Migraine Headache	N/A
Active, not recruiting	`NCT00285402` - Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine	Phase 2
Completed	`NCT00203255` - Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache	N/A
Recruiting	`NCT06046508` - Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)
Active, not recruiting	`NCT04584762` - Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine	N/A
Terminated	`NCT03099070` - Acute Stress Response in Migraine Sufferers	N/A